Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Candriam S.C.A.

Candriam S.C.A. increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 2.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 401,395 shares of the company’s stock after buying an additional 10,439 shares during the quarter. Candriam S.C.A. owned about 0.39% of Dyne Therapeutics worth $9,457,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Quantbot Technologies LP acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the third quarter worth $36,000. US Bancorp DE raised its position in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. KBC Group NV raised its position in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. Finally, Quest Partners LLC raised its position in shares of Dyne Therapeutics by 898.3% during the third quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock worth $123,000 after purchasing an additional 3,090 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on DYN shares. HC Wainwright cut their target price on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Robert W. Baird started coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. Piper Sandler cut their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Scotiabank started coverage on Dyne Therapeutics in a research report on Friday. They set a “sector outperform” rating and a $50.00 target price on the stock. Finally, Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.75.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,387 shares of company stock valued at $142,789 in the last three months. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $12.40 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $11.62 and a fifty-two week high of $47.45. The stock’s 50-day moving average is $16.03 and its two-hundred day moving average is $26.82. The firm has a market cap of $1.40 billion, a P/E ratio of -3.48 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.